Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form

Journal of Clinical Pharmacology

Volumn 47, Issue 1, 2007, Pages 64-69

  Tuerck, Dietrich ^a   Appel Dingemanse, Silke ^a   Maboudian, Mojdeh ^a   Pommier, Francoise ^b   Wang, Yibin ^a   Sedek, Greg ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

d MPH; Dose proportionality; Extended release; Human; Pharmacokinetics

Indexed keywords

DEXMETHYLPHENIDATE; DEXTRO THREO METHYLPHENIDATE; PIPERIDINE DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG MECHANISM; EXCITABILITY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; MALE; NORMAL HUMAN; SIDE EFFECT; TACHYCARDIA; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 33845723090     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006293757     Document Type: Article

References (17)

1. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am. 1992 ; 15: 191-222.
2. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry. 1977 ; 18: 137-165.
3. Kavale K. The efficacy of stimulant drug treatment for hyper-activity: a meta-analysis. J Learn Disabil. 1982 ; 15: 280-289.
4. Greenhill LL. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr Clin North Am. 1992 ; 15: 1-27.
5. Keating GM, Figgitt DP. Dexmethylphenidate. Drugs. 2002 ; 62: 1899-1904.
6. Patrick KS, Caldwell RW, Ferris RM, Breese GR. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther. 1987 ; 241: 152-158.
7. Srinivas NR, Hubbard J, Korchinski ED, Midha KK. Enantio-selective pharmacokinetics of dl-methylphenidate in humans. Pharm Res. 1993 ; 10: 14-21.
8. Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C] d-threo and l-threomethylphenidate in the human and baboon brain. Psychopharmacology. 1997 ; 131: 71-78.
9. Ding YS, Fowler JS, Volkow ND, Logan J, Gatley SJ, Sugano Y. Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J Nucl Med. 1995 ; 36: 2298-2305.
10. Sun Z, Murry DJ, Sanghani S, et al. Methylphenidate is stereo-selectively hydrolyzed by human carboxyesterase CES1A1. J Pharmacol Exp Ther. 2004 ; 310: 469-476.
11. Srinivas NR, Hubbard JW, Quinn D, Midha KK. Enantio-selective pharmacokinetics and pharmacodynamics of dl-threomethylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther. 1992 ; 52: 561-568.
12. Ballard JE, Boileau RA, Sleator EK, Massey BH, Sprague RL. Cardiovascular responses of hyperactive children to methylphenidate. JAMA. 1976 ; 236: 2870-2874.
13. Joyce PR, Nicholls MG, Donald RA. Methylphenidate increases heart rate, blood pressure and plasma epinephrine in normal subjects. Life Sci. 1984 ; 34: 1707-1711.
14. Wilens E, Biederman J, Lerner M, and the Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol. 2004 ; 24: 36-41.
15. Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs. 2002 ; 62 :51: 2251-2259.
16. Modi ND, Wang B, Noveck RJ, Gupta SK. Dose proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled release oral delivery system. J Clin Pharmacol. 2000 ; 40: 1141-1149.
17. Rochdi M, Gonzalez MA, Dirksen SJ. Dose proportional pharmacokinetics of a methylphenidate extended release capsule. Int J Clin Pharmacol Ther. 2004 ; 42: 285-292.